The Clinical Trials Core will support all investigators in the Dana-Farber/Harvard SPORE in Breast Cancer conducting clinical trials. The Clinical Trials Core will coordinate preparation, review and activation of clinical studies developed within the SPORE and Inter-SPORE programs. Additionally, the Clinical Trials Core will facilitate recruitment and consent of patients, clinical management and follow-up of patients, data collection and management and real-time monitoring of accrual and toxicity once trials are open. The Core will work closely with other SPORE Cores to coordinate all aspects of clinical research, including biostatistics support and biospecimen collection. The Core will utilize the Dana-Farber/Harvard Cancer Center data management infrastructure to facilitate the multi-center trials. The Core has resources available to achieve the aims outlined in the proposal, including dedicated Co-Directors, institutional commitment of clinical research coordinators and research nurses from all the institutions participating in clinical trials in the SPORE.

Public Health Relevance

The Clinical Trials Core centralizes support for SPORE investigators initiating clinical trials to increase efficiency, minimize delays and revisions, and maximize our ability to complete clinical trials in the SPORE. Streamlining the clinical trials process assures that clinical studies in the SPORE are conducted expeditiously and with the highest degree of scientific rigor, enhancing the likelihood they will provide translational results.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA168504-02
Application #
8753993
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$226,560
Indirect Cost
$87,298
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127
Kensler, Kevin H; Beca, Francisco; Baker, Gabrielle M et al. (2018) Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. NPJ Breast Cancer 4:33
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Guerriero, Jennifer L (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med 24:472-489
Kuang, Yanan; Siddiqui, Bilal; Hu, Jiani et al. (2018) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369
Sun, Bowen; Wang, Geng; Liu, Huidong et al. (2018) Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget 9:23878-23889
Willis, Nicholas A; Panday, Arvind; Duffey, Erin E et al. (2018) Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLoS Genet 14:e1007486

Showing the most recent 10 out of 66 publications